Cushman M, He H M, Katzenellenbogen J A, Varma R K, Hamel E, Lin C M, Ram S, Sachdeva Y P
Department of Medicinal Chemistry and Molecular Pharmacology, School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana 47907, USA.
J Med Chem. 1997 Jul 18;40(15):2323-34. doi: 10.1021/jm9700833.
A new series of estradiol analogs was synthesized in an attempt to improve on the anticancer activity of 2-methoxyestradiol, a naturally occurring mammalian tubulin polymerization inhibitor. The compounds were evaluated as inhibitors of tubulin polymerization and the binding of [3H]colchicine to tubulin, as well as for in vitro cytotoxicity in human cancer cell cultures. Overall, the most potent of the new compounds were 2-(2',2',2'-trifluoroethoxy)-6-oximinoestradiol, 2-ethoxy-6-oximinoestradiol, and 2-ethoxy-6-methoximinoestradiol. These agents lacked significant affinity for the estrogen receptor. The cytotoxicities of the compounds correlated in general with their abilities to inhibit tubulin polymerization, thus supporting inhibition of tubulin polymerization as the primary mechanism causing inhibition of cell growth.
合成了一系列新的雌二醇类似物,试图提高2-甲氧基雌二醇(一种天然存在的哺乳动物微管蛋白聚合抑制剂)的抗癌活性。对这些化合物进行了评估,测定其作为微管蛋白聚合抑制剂以及[3H]秋水仙碱与微管蛋白结合的抑制剂的活性,同时也检测了它们在人癌细胞培养物中的体外细胞毒性。总体而言,最有效的新化合物是2-(2',2',2'-三氟乙氧基)-6-肟基雌二醇、2-乙氧基-6-肟基雌二醇和2-乙氧基-6-甲氧基肟基雌二醇。这些药物对雌激素受体缺乏显著亲和力。这些化合物的细胞毒性总体上与其抑制微管蛋白聚合的能力相关,从而支持微管蛋白聚合抑制是导致细胞生长抑制的主要机制。